Reference Product

Key facts

Defined in

Public Health Service Act Section 351(i)(4)

Licensed under

Section 351(a) Biologics License Application

Exclusivity

12 years from first licensure; biosimilar filings barred for 4 years

Status shown in

FDA Purple Book

Small-molecule counterpart

Reference listed drug (RLD) in the Orange Book

What is a reference product?

In the biosimilar pathway, the reference product is the originator biologic whose earlier FDA licensure a biosimilar sponsor relies on. Examples include Humira (adalimumab), Herceptin (trastuzumab) and Neupogen (filgrastim), each of which has licensed biosimilars.

A biosimilar is evaluated against one reference product only. Sponsors may run some studies with a version of the product licensed outside the United States, but they must then provide bridging data that link it to the U.S.-licensed reference product.

How reference product exclusivity works

The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) protects reference products on two clocks, both measured from the date of first licensure:

• 4-year filing bar: no Section 351(k) biosimilar application may be submitted until 4 years after first licensure.
• 12-year approval bar: no biosimilar can be licensed until 12 years after first licensure.
• Limits on new clocks: later changes to the sponsor's product, such as a new indication, route or strength, generally do not start a new 12-year period unless a structural change also changes safety, purity or potency.
• Patents run separately: actual biosimilar launch often depends more on patent litigation and settlements than on the exclusivity date.

Why reference products matter

Reference product data anchor most biosimilar market analysis:

• Loss-of-exclusivity modeling: the 12-year date sets the earliest possible biosimilar approval and is the starting point for revenue erosion forecasts.
• Competitor mapping: the Purple Book links each biosimilar to its reference product, so analysts can count competitors per molecule.
• Payment benchmarks: Medicare Part B pays biosimilars an add-on based on the reference product's average sales price, so reference pricing affects biosimilar economics.
• Data hygiene: reference product, reference listed drug and reference standard are distinct regulatory terms and should not be merged in datasets.

Reference product vs reference listed drug

For small-molecule generics, the reference listed drug (RLD) is the approved product a generic applicant relies on, while the reference standard is the specific product the FDA selects for bioequivalence testing, usually but not always the RLD. Both appear in the Orange Book. Reference product is the biologics term and appears in the Purple Book.